-
公开(公告)号：CA3034876A1
公开(公告)日：2018-03-01
申请号：CA3034876
申请日：2017-08-23
Applicant: CHO PHARMA INC , ACADEMIA SINICA , LIN NAN HORNG
Inventor： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
-
公开(公告)号：AU2017315677B2
公开(公告)日：2021-03-11
申请号：AU2017315677
申请日：2017-08-23
Applicant: ACADEMIA SINICA , CHO PHARMA INC
Inventor： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN S , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
-
公开(公告)号：CA3034876C
公开(公告)日：2022-10-04
申请号：CA3034876
申请日：2017-08-23
Applicant: CHO PHARMA INC , ACADEMIA SINICA , LIN NAN HORNG
Inventor： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN S , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high transglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
-
公开(公告)号：AU2017315677A1
公开(公告)日：2019-04-11
申请号：AU2017315677
申请日：2017-08-23
Applicant: ACADEMIA SINICA , CHO PHARMA INC , LIN NAN HORNG
Inventor： LIN NAN-HORNG , HUANG LIN-YA , SHIVATARE SACHIN S , CHEN LI-TZU , WONG CHI-HUEY , WU CHUNG-YI , CHENG TING
Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
-
-
-
Search Results
4
records
(took 0.026 seconds)
